Can a malaria drug tame fatty liver? new trial aims to find out
NCT ID NCT07265297
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether hydroxychloroquine, a drug used for malaria and autoimmune diseases, can improve nonalcoholic steatohepatitis (NASH), a type of fatty liver with inflammation. 210 adults with confirmed fatty liver and elevated liver enzymes will take either 200 mg, 400 mg of HCQ, or a placebo daily for one year. The main goal is to see if HCQ lowers liver inflammation markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hydroxychloroquine
- What this could lead to
- If it works, this could provide a new treatment option for nonalcoholic steatohepatitis, a common liver condition with no approved therapies.
- What could go wrong
- This is a Phase 3 trial, but hydroxychloroquine has known side effects like eye damage and heart rhythm issues. The study is relatively small (210 people) and may not show clear benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEATOHEPATITIS, NONALCOHOLIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.